Cardiology

Treatment and Management

At a Glance

Ankyrin-B syndrome treatment is tailored to each person’s symptoms, heart rate and rhythm risk. Care may include monitoring, selected beta-blockers, a pacemaker for dangerously slow rhythms, or an ICD for life-threatening fast rhythms, and reviewing medicines that can destabilize the heart’s rhythm.

Because Ankyrin-B syndrome is a “broad” syndrome that looks different in every patient, there is no single “one-size-fits-all” treatment plan. Instead, your medical team will build a phenotype-based strategy—meaning they will treat the specific symptoms and heart patterns you actually have, rather than just treating the genetic variant itself ^[1]^[2].

Management is usually led by an electrophysiologist (a heart rhythm specialist) and focuses on three main goals: preventing dangerous rhythms, managing heart rate, and avoiding triggers ^[3]^[4].

Medications: The Role of Beta-Blockers

In many heart rhythm conditions, beta-blockers are the first line of defense. They work by blocking the effects of adrenaline (the “fight or flight” hormone) on the heart ^[5].

Nadolol: This is a specific type of long-acting beta-blocker often preferred for inherited rhythm issues ^[6].
The Evidence Gap: It is important to know that most evidence for using beta-blockers comes from “classic” Long QT Syndrome (Types 1, 2, and 3). There is very little human data specifically proving how well they work for all Ankyrin-B variants ^[1]^[7].
Limitations: Because Ankyrin-B can also cause a very slow heart rate (sinus bradycardia), beta-blockers must be used with caution. If your heart rate is already too slow, a beta-blocker could make it worse ^[8]^[2]. They are only prescribed when the treating specialist believes the expected benefit outweighs the bradycardia risk.

Procedural Options: Pacemakers and ICDs

For some patients, medications alone are not appropriate. In these cases, your doctor may discuss an implanted device, which is an individualized specialist decision:

Pacemakers: These are typically used if Ankyrin-B syndrome is causing your heart rate to drop dangerously low or if there is a “block” in the heart’s electrical signal ^[9]^[10]. A pacemaker ensures the heart never beats below a certain safe rate, but it is not interchangeable with an ICD.
Implantable Cardioverter-Defibrillators (ICDs): An ICD is a device that can deliver a life-saving shock if it detects a dangerous, fast rhythm (ventricular fibrillation) ^[11].
- Secondary Prevention: ICDs are strongly recommended for anyone who has survived a sudden cardiac arrest or a life-threatening rhythm event ^[12].
- Primary Prevention: For those who haven’t had a major event, an ICD decision is mainly based on documented ventricular arrhythmias and carefully individualized risk ^[13]^[14].

Medications to Review: QT-Prolonging Drugs

One of the important parts of your care is reviewing substances that could further destabilize your heart’s electricity. Many common medications can “prolong the QT interval,” which can interact with an ANK2 variant ^[1]^[15].

You should not stop a prescribed medicine unilaterally, but you should review new medications with your clinician or pharmacist, checking resources like CredibleMeds. Classes to watch out for include:

Certain Antibiotics: Such as azithromycin or clarithromycin ^[16].
Some Antidepressants and Antipsychotics: Which can affect heart recharging ^[15]^[17].
Anti-nausea Drugs: Like ondansetron ^[18].
Electrolyte Imbalances: Low potassium or magnesium can make your heart more vulnerable to triggers ^[15]^[19]. Seek medical care to measure and correct low electrolytes rather than self-treating with supplements.

Individualized Risk Profiles

Your treatment path is not a straight line; it is a series of decisions based on your unique profile:

Low Risk Profiles (No symptoms, normal heart tests): Often managed with “watchful waiting,” regular clinical check-ups, and reviewing QT-prolonging drugs ^[14]^[20].
Moderate Risk Profiles (Mild QT prolongation or slow heart rate): May involve individualized use of beta-blockers and more frequent monitoring with heart-rate trackers ^[1]^[7].
High Risk Profiles (History of fainting, severe rhythm issues, or prior arrest): Typically requires specialized treatment which may include an ICD or pacemaker depending on the specific rhythm ^[11]^[13].

Always remember that a genetic variant is only one part of the story. Your clinical symptoms and how your heart responds to treatment are the most important factors in keeping you safe ^[3]^[21]. If you develop atrial fibrillation, it will require its own separate rate and rhythm management, along with an individualized assessment of stroke prevention needs.

Common questions in this guide

How is Ankyrin-B syndrome treated?

There is no single treatment plan for Ankyrin-B syndrome. A heart-rhythm specialist tailors care to your symptoms, heart rate, rhythm findings, and history, with goals of preventing dangerous rhythms, controlling heart rate, and avoiding triggers.

Can beta-blockers be used for Ankyrin-B syndrome?

Beta-blockers such as nadolol may be considered, but evidence specifically in Ankyrin-B syndrome is limited and often comes from other forms of Long QT syndrome. Because they can worsen an already slow heart rate, they should be prescribed and monitored by your treating specialist.

When might I need a pacemaker?

A pacemaker may be considered when Ankyrin-B syndrome causes a dangerously slow heart rate or a block in the heart’s electrical signals. It maintains a minimum heart rate, but it is not the same as an ICD and does not deliver shocks for dangerous fast rhythms.

When is an ICD considered?

An ICD is strongly recommended for people who have survived sudden cardiac arrest or another life-threatening rhythm event. In people without such a history, the decision depends on documented ventricular arrhythmias and an individualized assessment of risk.

Which medicines and health factors should I review with my doctor?

Some antibiotics, antidepressants, antipsychotics, and anti-nausea medicines can prolong the QT interval, and low potassium or magnesium can increase rhythm risk. Ask your clinician or pharmacist to review new prescriptions and supplements, and do not stop a prescribed medicine on your own.

What if I develop atrial fibrillation with Ankyrin-B syndrome?

Atrial fibrillation needs its own plan for controlling the heart rate or rhythm. Your clinician will also assess whether you need stroke prevention, based on your overall risk and medical history.

Get notified when new evidence is published on Cardiac arrhythmia, ankyrin-b-related.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Ankyrin-B syndrome has no single treatment plan; a heart-rhythm specialist tailors care to symptoms, heart rate, rhythm findings, and event history.
Beta-blockers such as nadolol may help some patients, but they require caution because they can worsen sinus bradycardia and evidence for Ankyrin-B variants is limited.
Pacemakers address dangerously slow heart rates or heart block, whereas ICDs treat dangerous fast rhythms and are strongly recommended after a life-threatening rhythm event.
Certain antibiotics, antidepressants, antipsychotics, and anti-nausea medicines can prolong the QT interval, while low potassium or magnesium can increase rhythm risk.
Risk-based follow-up may include regular monitoring, and atrial fibrillation requires separate assessment for rate or rhythm control and stroke prevention.

References (21)

1
Phenotypic Variability of ANK2 Mutations in Patients With Inherited Primary Arrhythmia Syndromes.
Ichikawa M, Aiba T, Ohno S, et al.
Circulation journal : official journal of the Japanese Circulation Society 2016; (80(12)):2435-2442 doi:10.1253/circj.CJ-16-0486.
PMID: 27784853
2
The evolving role of ankyrin-B in cardiovascular disease.
Koenig SN, Mohler PJ
Heart rhythm 2017; (14(12)):1884-1889 doi:10.1016/j.hrthm.2017.07.032.
PMID: 28765088
3
Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics.
Arbustini E, Behr ER, Carrier L, et al.
European heart journal 2022; (43(20)):1901-1916 doi:10.1093/eurheartj/ehab895.
PMID: 35089333
4
Genetic analysis of Iranian family with hereditary cardiac arrhythmias by next generation sequencing.
Asadi M, Foo R, Samienasab MR, et al.
Advanced biomedical research 2016; (5()):55 doi:10.4103/2277-9175.178801.
PMID: 27110552
5
Does sports participation increase risk in patients with long QT syndrome? Results from a large French cohort.
Davydoff C, Andorin A, Minois D, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(10)):1675-1683 doi:10.1093/europace/euac047.
PMID: 35951747
6
[Analyses of triggers for recurrent cardiac events in 38 patients with symptomatic long QT syndrome].
Li K, She F, Yang J, et al.
Zhonghua xin xue guan bing za zhi 2021; (49(2)):165-169 doi:10.3760/cma.j.cn112148-20200529-00443.
PMID: 33611903
7
Ankyrin-B Q1283H Variant Linked to Arrhythmias Via Loss of Local Protein Phosphatase 2A Activity Causes Ryanodine Receptor Hyperphosphorylation.
Zhu W, Wang C, Hu J, et al.
Circulation 2018; (138(23)):2682-2697 doi:10.1161/CIRCULATIONAHA.118.034541.
PMID: 30571258
8
Long QT Syndrome and Sinus Bradycardia-A Mini Review.
Wilders R, Verkerk AO
Frontiers in cardiovascular medicine 2018; (5()):106 doi:10.3389/fcvm.2018.00106.
PMID: 30123799
9
High-degree atrioventricular block in a child with an ANK2 variant and long QT phenotype requiring leadless pacemaker implantation.
You J
Cardiology in the young 2026; (36(7)):1532-1535 doi:10.1017/S1047951126123464.
PMID: 42493853
10
New Guidelines of Pediatric Cardiac Implantable Electronic Devices: What Is Changing in Clinical Practice?
Silvetti MS, Colonna D, Gabbarini F, et al.
Journal of cardiovascular development and disease 2024; (11(4)) doi:10.3390/jcdd11040099.
PMID: 38667717
11
Management of channelopathies in children.
Krause U
Herzschrittmachertherapie & Elektrophysiologie 2025; (36(3)):186-191 doi:10.1007/s00399-025-01098-2.
PMID: 40762707
12
Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome.
Wang M, Peterson DR, Rosero S, et al.
Journal of the American College of Cardiology 2021; (78(21)):2076-2088 doi:10.1016/j.jacc.2021.09.017.
PMID: 34794689
13
Catheter and Device Management of Inherited Cardiac Conditions.
Bennett R, Campbell T, Kumar S
Heart, lung & circulation 2020; (29(4)):594-606 doi:10.1016/j.hlc.2019.12.009.
PMID: 32014423
14
Mechanisms underlying the role of ankyrin-B in cardiac and neurological health and disease.
York NS, Sanchez-Arias JC, McAdam ACH, et al.
Frontiers in cardiovascular medicine 2022; (9()):964675 doi:10.3389/fcvm.2022.964675.
PMID: 35990955
15
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Cubeddu LX
Current cardiology reviews 2016; (12(2)):141-54 doi:10.2174/1573403x12666160301120217.
PMID: 26926294
16
Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.
Weeke PE, Kellemann JS, Jespersen CB, et al.
European heart journal 2019; (40(37)):3110-3117 doi:10.1093/eurheartj/ehz228.
PMID: 31079148
17
Drug-specific risk of severe QT prolongation following acute drug overdose.
Campleman SL, Brent J, Pizon AF, et al.
Clinical toxicology (Philadelphia, Pa.) 2020; (58(12)):1326-1334 doi:10.1080/15563650.2020.1746330.
PMID: 32252558
18
Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome.
Moustafa AT, Dabash O, Panigrahi PK, Khan HR
European heart journal. Cardiovascular pharmacotherapy 2026; (12(7)):556-567 doi:10.1093/ehjcvp/pvag077.
PMID: 42748473
19
Pharmacological treatment of acquired QT prolongation and torsades de pointes.
Thomas SH, Behr ER
British journal of clinical pharmacology 2016; (81(3)):420-7 doi:10.1111/bcp.12726.
PMID: 26183037
20
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk).
Mazzanti A, Trancuccio A, Kukavica D, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(4)):614-619 doi:10.1093/europace/euab238.
PMID: 34505884
21
The frequency of gene variant reclassification and its impact on clinical management in the inherited arrhythmia clinic.
Young WJ, Maung S, Ahmet S, et al.
Heart rhythm 2024; (21(6)):903-910 doi:10.1016/j.hrthm.2024.01.008.
PMID: 38218330

This page provides general information about Ankyrin-B syndrome treatment and does not constitute medical advice. Do not start, stop, or change medicines or implanted-device plans without guidance from your heart-rhythm specialist or pharmacist.